Sensus Healthcare (SRTS) Projected to Post Earnings on Thursday

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) is projected to post its Q1 2025 earnings data after the market closes on Thursday, May 15th. Analysts expect Sensus Healthcare to post earnings of $0.04 per share and revenue of $7.23 million for the quarter.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. On average, analysts expect Sensus Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sensus Healthcare Stock Performance

NASDAQ SRTS remained flat at $4.33 during trading on Friday. 129,345 shares of the company's stock traded hands, compared to its average volume of 311,211. The business's 50-day moving average price is $4.63 and its two-hundred day moving average price is $6.27. Sensus Healthcare has a twelve month low of $3.61 and a twelve month high of $9.33. The firm has a market cap of $71.42 million, a price-to-earnings ratio of 10.83 and a beta of 1.11.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on SRTS shares. HC Wainwright reissued a "buy" rating and set a $12.00 target price on shares of Sensus Healthcare in a research note on Friday, April 4th. Lake Street Capital reduced their price objective on shares of Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.